EGFR‐TKI such as erlotinib (Rosell et al, 2012), gefitinib (Mok et al, 2009), and afatinib (Sequist et al, 2013) have shown clinical activity toward NSCLC, leading to their approval for the treatment of metastatic disease. The gene discussed is EGFR; the disease is metastatic neoplasm.